In the last trading session, 1.08 million EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares changed hands as the company’s beta touched 1.65. With the company’s per share price at $4.13 changed hands at -$0.49 or -10.61% during last session, the market valuation stood at $283.85M. EYPT’s last price was a discount, traded about -472.64% off its 52-week high of $23.65. The share price had its 52-week low at $4.19, which suggests the last value was -1.45% down since then. When we look at EyePoint Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.91 million shares, with the 3-month average coming to 841.88K.
Analysts gave the EyePoint Pharmaceuticals Inc (EYPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EYPT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Instantly EYPT was in red as seen at the end of in last trading. With action -18.22%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -44.56%, with the 5-day performance at -18.22% in the red. However, in the 30-day time frame, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is -41.75% down. Looking at the short shares, we see there were 10.83 million shares sold at short interest cover period of 13.37 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 81.23% from its current market value. According to analyst projections, EYPT’s forecast low is 22 with 22 as the target high. To hit the forecast high, the stock’s price needs a -432.69% plunge from its current level, while the stock would need to soar -432.69% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 15.65%. The 2025 estimates are for EyePoint Pharmaceuticals Inc earnings to decrease by -22.68%, but the outlook for the next 5-year period is at 0.67% per year.
EYPT Dividends
EyePoint Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Mar-04.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.16% of EyePoint Pharmaceuticals Inc shares while 109.63% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.92%. There are 109.63% institutions holding the EyePoint Pharmaceuticals Inc stock share, with CORMORANT ASSET MANAGEMENT, LP the top institutional holder. As of 2024-06-30, the company held 15.6467% of the shares, roughly 8.32 million EYPT shares worth $72.43 million.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 9.7279% or 5.18 million shares worth $45.03 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.04 shares estimated at $8.42 million under it, the former controlled 2.97% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.89% of the shares, roughly 1.99 shares worth around $8.21 million.
